1). Naruse K, Nagashima H, Sakai Y, Kokudo N, Makuuchi M. Development and perspectives of perfusion treatment for liver failure. Surg Today. 2005; 35:507–17.
Article
2). Chiu A, Chan LM, Fan ST. Molecular adsorbent recirculating system treatment for patients with liver failure: the Hong Kong experience. Liver Int. 2006; 26:695–702.
Article
3). Gaspari R, Avolio AW, Zileri Dal Verme L, Agnes S, Proietti R, Castagneto M, et al. Molecular adsorbent recirculating system in liver transplantation: safety and efficacy. Transplant Proc. 2006; 38:3544–51.
Article
4). Ozdemir FN, Tutal E, Sezer S, Gür G, Bilgic A, Haberal M. Effect of supportive extracorporeal treatment in liver transplantation recipients and advanced liver failure patients. Hemodial Int. 2006; 10(S2):28–32.
Article
5). Lee SG, Hwang S, Kim KH, Ahn CS, Moon DB, Ha TY, et al. Toward 300 liver transplants a year. Surg Today. 2009; 39:367–73.
Article
6). Schmidt LE, Wang LP, Hansen BA, Larsen FS. Systemic hemodynamic effects of treatment with the molecular ad-sorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transpl. 2003; 9:290–7.
Article
7). Hetz H, Faybik P, Berlakovich G, Baker A, Bacher A, Burghuber C, et al. Molecular adsorbent recirculating system in patients with early allograft dysfunction after liver transplantation: a pilot study. Liver Transpl. 2006; 12:1357–64.
Article
8). Kellersmann R, Gassel HJ, Bühler C, Thiede A, Timmermann W. Application of Molecular Adsorbent Recirculating System in patients with severe liver failure after hepatic resection or transplantation: initial sin-gle-centre experiences. Liver. 2002; 22(S2):56–8.
Article
9). Steiner C, Mitzner S. Experiences with MARS liver support therapy in liver failure: analysis of 176 patients of the International MARS Registry. Liver. 2002; 22(S2):20–5.
10). Gaspari R, Cavaliere F, Sollazzi L, Perilli V, Melchionda I, Agnes S, et al. Molecular adsorbent recirculating system (Mars) in patients with primary nonfunction and other causes of graft dysfunction after liver transplantation in the era of extended criteria donor organs. Transplant Proc. 2009; 41:253–8.
Article
11). Novelli G, Rossi M, Pretagostini M, Pugliese F, Ruberto F, Novelli L, et al. One hundred sixteen cases of acute liver failure treated with MARS. Transplant Proc. 2005; 37:2557–9.
Article
12). Akdogan M, Camci C, Gurakar A, Gilcher R, Alamian S, Wright H, et al. The effect of total plasma exchange on fulminant hepatic failure. J Clin Apher. 2006; 21:96–9.
Article
13). Bektas M, Idilman R, Soykan I, Soydan E, Arat M, Cinar K, et al. Adjuvant therapeutic plasma exchange in liver failure: assessments of clinical and laboratory parameters. J Clin Gastroenterol. 2008; 42:517–21.
14). Hwang S, Ha TY, Ahn CS, Kim KH, Lee SG. Reappraisal of plasmapheresis as a supportive measure in a patient with hepatic failure after major hepatectomy. Case Rep Gastroenterol. 2007; 1:162–7.
Article
15). Buckner CD, Clift RA, Volwiler W, Donohue DM, Burnell JM, Saunders FC, et al. Plasma exchange in patients with fulminant hepatic failure. Arch Intern Med. 1973; 132:487–92.
Article
16). Mandal AK, King KE, Humphreys SL, Maley WR, Burdick JF, Klein AS. Plasmapheresis: an effective therapy for primary allograft nonfunction after liver transplantation. Transplantation. 2000; 70:216–20.
17). Morimoto T, Matsushima M, Sowa N, Ide K, Sawanishi K. Plasma adsorption using bilirubin-adsorbent materials as a treatment for patients with hepatic failure. Artif Organs. 1989; 13:447–52.
Article
18). Singer AL, Olthoff KM, Kim H, Rand E, Zamir G, Shaked A. Role of plasmapheresis in the management of acute hepatic failure in children. Ann Surg. 2001; 234:418–24.
Article
19). Camci C, Akdogan M, Gurakar A, Gilcher R, Rose J, Monlux R, et al. The impact of total plasma exchange on early allograft dysfunction. Transplant Proc. 2004; 36:2567–9.
Article
20). Hwang S, Lee SG, Jung DH, Kim KH, Ha TY, Song GW. Simulation of deceased-donor liver graft allocation as UNOS status I or IIa on the current Korean setting for patients with hepatitis B virus-induced fulminant hepatic failure. Korean J Hepatobiliary Pancreat Surg. 2009; 13:31–6.
21). Yamamoto R, Nagasawa Y, Marubashi S, Furumatsu Y, Iwatani H, Iio K, et al. Early plasma exchange for pro-gressive liver failure in recipients of adult-to-adult living-related liver transplants. Blood Purif. 2009; 28:40–6.
Article
22). Bektas M, Idilman R, Soykan I, Soydan E, Arat M, Cinar K, et al. Adjuvant therapeutic plasma exchange in liver failure: assessments of clinical and laboratory parameters. J Clin Gastroenterol. 2008; 42:517–21.
23). Gui D, Spada PL, de Gaetano A, Pacelli F. Hypochole-sterolemia and risk of death in the critically ill surgical patient. Intensive Care Med. 1996; 22:790–4.
Article
24). Giovannini I, Boldrini G, Chiarla C, Giuliante F, Vellone M, Nuzzo G. Pathophysiologic correlates of hypochole-sterolemia in critically ill surgical patients. Intensive Care Med. 1999; 25:748–51.
Article